The Global Antibiotic Research & Development Partnership (GARDP)

Discussion on the importance of access to antibiotics and new antimicrobial agents against drug-resistant organisms in combating antimicrobial resistance, as well as the role of GARP in accelerating development and access of treatment for drug-resistant bacterial infections.

Exploration of the origins of GARP and its objective to ensure appropriate access to antibiotics for critical drug-resistant infections globally, focusing on patients who need them regardless of location.

Insight into the main funders of GARP, including philanthropic organizations like the Bill and Melinda Gates Foundation and government entities, to support product development and access initiatives.

Discussion on the role of GARP in Latin America and the Caribbean, addressing the challenges and initiatives to combat antimicrobial resistance in the region, focusing on collaboration with Pan-American Health Organization and research institutes.

Explanation of GARP's strategy to ensure access to new drugs in low and middle-income countries, emphasizing the importance of global perspective in drug development and access to meet the needs of a larger population.

Details on ensuring quality assurance in drug production through partnerships with pharmaceutical companies and smaller manufacturers, focusing on stringent regulatory standards, affordability, and public health priorities.

Insight into maintaining affordable drug prices through margin control, sub-license agreements, and strategic partnerships to ensure access and availability of treatments in different countries, including Latin America.

Explanation of the role of implementation research in generating evidence for drug efficacy and public health impact, emphasizing the importance of continuous learning and adaptation in addressing antimicrobial resistance.

Optimistic outlook on future progress in combating antimicrobial resistance through collaboration, regional capacity-building, and strengthening research and manufacturing capabilities in the antibiotic field.